Tokyo Tape
Sign in
← Otsuka Holdings

Quarterly report · Q1

4578.TEDINET S100TCFM
Period2024-01-01 → 2024-03-31
Filed2024-04-30
StandardIFRS
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 47
MetricValuePeriodScopeSource row
Revenue¥519.5bn2024-01-01 → 2024-03-31Cons.Revenue IFRS
Revenue¥2.02T2023-01-01 → 2023-12-31Cons.Revenue IFRS (5-year summary)
Revenue¥448.3bn2023-01-01 → 2023-03-31Cons.Revenue IFRS
Operating income¥92.0bn2024-01-01 → 2024-03-31Cons.Operating profit loss IFRS
Operating income¥76.8bn2023-01-01 → 2023-03-31Cons.Operating profit loss IFRS
Profit before tax¥100.1bn2024-01-01 → 2024-03-31Cons.Profit loss before tax IFRS
Profit before tax¥142.7bn2023-01-01 → 2023-12-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥79.2bn2023-01-01 → 2023-03-31Cons.Profit loss before tax IFRS
Net income (owners)¥77.4bn2024-01-01 → 2024-03-31Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥121.6bn2023-01-01 → 2023-12-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥61.4bn2023-01-01 → 2023-03-31Cons.Profit loss attributable to owners of parent IFRS
Net income¥78.9bn2024-01-01 → 2024-03-31Cons.Profit loss IFRS
Net income¥62.7bn2023-01-01 → 2023-03-31Cons.Profit loss IFRS
Total assets¥3.45Tat 2024-03-31Cons.Assets IFRS
Total assets¥3.36Tat 2023-12-31Cons.Assets IFRS
Total assets¥3.13Tat 2023-03-31Cons.Total assets IFRS (5-year summary)
Total liabilities¥894.5bnat 2024-03-31Cons.Liabilities IFRS
Total liabilities¥924.9bnat 2023-12-31Cons.Liabilities IFRS
Net assets / equity¥2.56Tat 2024-03-31Cons.Equity IFRS
Net assets / equity¥2.44Tat 2023-12-31Cons.Equity IFRS
Net assets / equity¥2.32Tat 2023-03-31Cons.Equity IFRS
Net assets / equity¥2.26Tat 2022-12-31dCons.Equity IFRS
Equity (owners)¥2.51Tat 2024-03-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥2.39Tat 2023-12-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥2.28Tat 2023-03-31Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥411.6bnat 2024-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥513.3bnat 2023-12-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥477.1bnat 2023-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥471.6bnat 2022-12-31dCons.Cash and cash equivalents IFRS
Operating cash flow¥36.4bn2024-01-01 → 2024-03-31Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥283.2bn2023-01-01 → 2023-12-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥71.9bn2023-01-01 → 2023-03-31Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥91.5bn2024-01-01 → 2024-03-31Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥190.5bn2023-01-01 → 2023-12-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥35.8bn2023-01-01 → 2023-03-31Cons.Net cash provided by used in investing activities IFRS
Financing cash flow−¥58.7bn2024-01-01 → 2024-03-31Cons.Net cash provided by used in financing activities IFRS
Financing cash flow−¥60.3bn2023-01-01 → 2023-12-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow−¥32.7bn2023-01-01 → 2023-03-31Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥142.592024-01-01 → 2024-03-31Cons.Basic earnings loss per share IFRS
EPS (basic)¥224.12023-01-01 → 2023-12-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥113.22023-01-01 → 2023-03-31Cons.Basic earnings loss per share IFRS
EPS (diluted)¥142.592024-01-01 → 2024-03-31Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥224.12023-01-01 → 2023-12-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥113.182023-01-01 → 2023-03-31Cons.Diluted earnings loss per share IFRS
Equity ratio72.8%at 2024-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio71.2%at 2023-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio72.8%at 2023-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 44
SegmentItemPeriodValue
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2024-01-01 → 2024-03-31¥27.3bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2024-01-01 → 2024-03-31¥26.4bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2024-01-01 → 2024-03-31¥872m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2024-01-01 → 2024-03-31¥1.9bn
Reconciling Itemsreconcilingrevenue2024-01-01 → 2024-03-31−¥881m
Reconciling Itemsreconcilingrevenue intersegment2024-01-01 → 2024-03-31−¥881m
Reconciling Itemsreconcilingsegment profit2024-01-01 → 2024-03-31−¥10.8bn
jpcrp040300-q1r_E21183-000Consumer Productsreportable segmentrevenue2024-01-01 → 2024-03-31¥7.3bn
jpcrp040300-q1r_E21183-000Consumer Productsreportable segmentrevenue external2024-01-01 → 2024-03-31¥7.3bn
jpcrp040300-q1r_E21183-000Consumer Productsreportable segmentrevenue intersegment2024-01-01 → 2024-03-31¥1m
jpcrp040300-q1r_E21183-000Consumer Productsreportable segmentsegment profit2024-01-01 → 2024-03-31¥4.3bn
jpcrp040300-q1r_E21183-000Nutraceuticalsreportable segmentrevenue2024-01-01 → 2024-03-31¥126.2bn
jpcrp040300-q1r_E21183-000Nutraceuticalsreportable segmentrevenue external2024-01-01 → 2024-03-31¥126.2bn
jpcrp040300-q1r_E21183-000Nutraceuticalsreportable segmentrevenue intersegment2024-01-01 → 2024-03-31¥6m
jpcrp040300-q1r_E21183-000Nutraceuticalsreportable segmentsegment profit2024-01-01 → 2024-03-31¥16.8bn
jpcrp040300-q1r_E21183-000Pharmaceuticalsreportable segmentrevenue2024-01-01 → 2024-03-31¥359.6bn
jpcrp040300-q1r_E21183-000Pharmaceuticalsreportable segmentrevenue external2024-01-01 → 2024-03-31¥359.6bn
jpcrp040300-q1r_E21183-000Pharmaceuticalsreportable segmentsegment profit2024-01-01 → 2024-03-31¥79.8bn
—segment totalrevenue2024-01-01 → 2024-03-31¥520.4bn
—segment totalrevenue external2024-01-01 → 2024-03-31¥519.5bn
—segment totalrevenue intersegment2024-01-01 → 2024-03-31¥881m
—segment totalsegment profit2024-01-01 → 2024-03-31¥102.8bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2023-01-01 → 2023-03-31¥27.3bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2023-01-01 → 2023-03-31¥26.6bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2023-01-01 → 2023-03-31¥723m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2023-01-01 → 2023-03-31¥3.1bn
Reconciling Itemsreconcilingrevenue2023-01-01 → 2023-03-31−¥742m
Reconciling Itemsreconcilingrevenue intersegment2023-01-01 → 2023-03-31−¥742m
Reconciling Itemsreconcilingsegment profit2023-01-01 → 2023-03-31−¥12.9bn
jpcrp040300-q1r_E21183-000Consumer Productsreportable segmentrevenue2023-01-01 → 2023-03-31¥8.2bn
jpcrp040300-q1r_E21183-000Consumer Productsreportable segmentrevenue external2023-01-01 → 2023-03-31¥8.2bn
jpcrp040300-q1r_E21183-000Consumer Productsreportable segmentrevenue intersegment2023-01-01 → 2023-03-31¥4m
jpcrp040300-q1r_E21183-000Consumer Productsreportable segmentsegment profit2023-01-01 → 2023-03-31¥2.2bn
jpcrp040300-q1r_E21183-000Nutraceuticalsreportable segmentrevenue2023-01-01 → 2023-03-31¥104.0bn
jpcrp040300-q1r_E21183-000Nutraceuticalsreportable segmentrevenue external2023-01-01 → 2023-03-31¥104.0bn
jpcrp040300-q1r_E21183-000Nutraceuticalsreportable segmentrevenue intersegment2023-01-01 → 2023-03-31¥13m
jpcrp040300-q1r_E21183-000Nutraceuticalsreportable segmentsegment profit2023-01-01 → 2023-03-31¥10.8bn
jpcrp040300-q1r_E21183-000Pharmaceuticalsreportable segmentrevenue2023-01-01 → 2023-03-31¥309.5bn
jpcrp040300-q1r_E21183-000Pharmaceuticalsreportable segmentrevenue external2023-01-01 → 2023-03-31¥309.5bn
jpcrp040300-q1r_E21183-000Pharmaceuticalsreportable segmentsegment profit2023-01-01 → 2023-03-31¥73.6bn
—segment totalrevenue2023-01-01 → 2023-03-31¥449.1bn
—segment totalrevenue external2023-01-01 → 2023-03-31¥448.3bn
—segment totalrevenue intersegment2023-01-01 → 2023-03-31¥742m
—segment totalsegment profit2023-01-01 → 2023-03-31¥89.7bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 694
ItemContextValueUnit
Non controlling interests IFRSCurrentQuarterInstant43668000000JPY
Equity IFRSPrior1YearInstant2436317000000JPY
Equity IFRSCurrentQuarterInstant2555254000000JPY
Liabilities and equity IFRSPrior1YearInstant3361244000000JPY
Liabilities and equity IFRSCurrentQuarterInstant3449786000000JPY
Revenue IFRSPrior1YTDDuration448344000000JPY
Revenue IFRSCurrentYTDDuration519517000000JPY
Cost of sales IFRSPrior1YTDDuration136776000000JPY
Cost of sales IFRSCurrentYTDDuration151802000000JPY
Gross profit IFRSPrior1YTDDuration311567000000JPY
Gross profit IFRSCurrentYTDDuration367715000000JPY
Selling general and administrative expenses IFRSPrior1YTDDuration175558000000JPY
Selling general and administrative expenses IFRSCurrentYTDDuration213750000000JPY
Share of profit loss of investments accounted for using equity method IFRSPrior1YTDDuration5640000000JPY
Share of profit loss of investments accounted for using equity method IFRSCurrentYTDDuration7387000000JPY
Research and development expenditure recognized as expense during period IFRSPrior1YTDDuration67968000000JPY
Research and development expenditure recognized as expense during period IFRSCurrentYTDDuration72387000000JPY
Impairment losses pl IFRSPrior1YTDDuration211000000JPY
Impairment losses pl IFRSCurrentYTDDuration125000000JPY
Other income IFRSPrior1YTDDuration3848000000JPY
Other income IFRSCurrentYTDDuration3602000000JPY
Other expenses IFRSPrior1YTDDuration538000000JPY
Other expenses IFRSCurrentYTDDuration421000000JPY
Operating profit loss IFRSPrior1YTDDuration76779000000JPY
Operating profit loss IFRSCurrentYTDDuration92021000000JPY
Finance income IFRSPrior1YTDDuration3884000000JPY
Finance income IFRSCurrentYTDDuration10092000000JPY
Finance costs IFRSPrior1YTDDuration1421000000JPY
Finance costs IFRSCurrentYTDDuration2034000000JPY
Profit loss before tax IFRSPrior1YTDDuration79242000000JPY
Profit loss before tax IFRSCurrentYTDDuration100079000000JPY
Income tax expense IFRSPrior1YTDDuration16579000000JPY
Income tax expense IFRSCurrentYTDDuration21182000000JPY
Profit loss IFRSPrior1YTDDuration62663000000JPY
Profit loss IFRSCurrentYTDDuration78896000000JPY
Profit loss attributable to owners of parent IFRSPrior1YTDDuration61430000000JPY
Profit loss attributable to owners of parent IFRSCurrentYTDDuration77377000000JPY
Profit loss attributable to non controlling interests IFRSPrior1YTDDuration1232000000JPY
Profit loss attributable to non controlling interests IFRSCurrentYTDDuration1518000000JPY
Profit loss IFRSPrior1YTDDuration62663000000JPY
Profit loss IFRSCurrentYTDDuration78896000000JPY
Basic earnings loss per share IFRSPrior1YTDDuration113.20
Basic earnings loss per share IFRSCurrentYTDDuration142.59
Diluted earnings loss per share IFRSPrior1YTDDuration113.18
Diluted earnings loss per share IFRSCurrentYTDDuration142.59
Profit loss IFRSPrior1YTDDuration62663000000JPY
Profit loss IFRSCurrentYTDDuration78896000000JPY
Remeasurements of defined benefit plans net of tax items that will not be reclassified to profit or loss oci IFRSPrior1YTDDuration20000000JPY
Remeasurements of defined benefit plans net of tax items that will not be reclassified to profit or loss oci IFRSCurrentYTDDuration148000000JPY
Net change in fair value of equity instruments designated as measured at fair value through other comprehensive income net of tax items that will not be reclassified to profit or loss oci IFRSPrior1YTDDuration4125000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2023-12-31pass rounding
balance sheet identityconsolidated 2024-03-31pass
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2023-01-01/2023-03-31pass
statement vs summary · net income attributable to parentconsolidated 2024-01-01/2024-03-31pass
statement vs summary · operating cash flowconsolidated 2023-01-01/2023-03-31pass
statement vs summary · operating cash flowconsolidated 2024-01-01/2024-03-31pass
statement vs summary · revenueconsolidated 2023-01-01/2023-03-31pass
statement vs summary · revenueconsolidated 2024-01-01/2024-03-31pass
statement vs summary · total assetsconsolidated 2023-12-31pass
statement vs summary · total assetsconsolidated 2024-03-31pass